Clinical Trial Update: Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of PCI-32765 (ibrutinib) and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• PCI-32765 (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-09-18